Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Cost of Revenue (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Cost of Revenue for 6 consecutive years, with $700000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 170.27% year-over-year to $700000.0, compared with a TTM value of $1.2 million through Dec 2025, up 35.55%, and an annual FY2025 reading of $911000.0, down 43.03% over the prior year.
  • Cost of Revenue was $700000.0 for Q4 2025 at Roivant Sciences, up from $111000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $8.5 million in Q4 2021 and bottomed at $111000.0 in Q3 2025.
  • Average Cost of Revenue over 5 years is $2.1 million, with a median of $700000.0 recorded in 2025.
  • The sharpest move saw Cost of Revenue skyrocketed 792.45% in 2021, then plummeted 94.95% in 2024.
  • Year by year, Cost of Revenue stood at $8.5 million in 2021, then crashed by 57.85% to $3.6 million in 2022, then crashed by 94.51% to $197000.0 in 2023, then skyrocketed by 31.47% to $259000.0 in 2024, then soared by 170.27% to $700000.0 in 2025.
  • Business Quant data shows Cost of Revenue for ROIV at $700000.0 in Q4 2025, $111000.0 in Q3 2025, and $154000.0 in Q2 2025.